Wegovy Clinical Trial Results UK - From £69.00

Clinically Proven UK Registered Pharmacy

Cheapest Wegovy UK Price - From £69.00

Get Wegovy at the cheapest UK price from £69.00 with £20 off first order using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £69.00

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Wegovy Clinical Trial Results: Evidence-Based Weight Loss Data

Wegovy clinical trial results from the landmark STEP programme demonstrate significant weight loss outcomes for adults with obesity. Across multiple phase 3 trials involving over 4,500 participants, semaglutide 2.4mg (Wegovy) consistently delivered average weight reductions of 12-15% from baseline body weight over 68 weeks[1]. These robust clinical findings have positioned Wegovy as one of the most evidence-backed weight management treatments licensed by the MHRA for UK patients.

STEP Trial Programme: Wegovy Clinical Trial Results Overview

The Wegovy clinical trial results stem primarily from the STEP (Semaglutide Treatment Effect in People with obesity) programme, a comprehensive series of randomised, double-blind, placebo-controlled trials conducted across multiple countries including UK sites[1]. The STEP 1 trial, published in The New England Journal of Medicine, enrolled 1,961 adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities. Participants receiving once-weekly semaglutide 2.4mg achieved a mean weight loss of 14.9% at 68 weeks, compared to 2.4% in the placebo group[1].

Subsequent trials in the STEP series examined specific populations and treatment scenarios. STEP 2 focused on adults with type 2 diabetes, demonstrating 9.6% average weight reduction with Wegovy versus 3.4% with placebo[2]. STEP 3 combined semaglutide with intensive behavioural therapy, yielding 16.0% mean weight loss[2]. STEP 4 evaluated weight maintenance after initial treatment, showing participants who continued Wegovy maintained their weight loss whilst those switched to placebo regained 6.9% of body weight[3]. These wegovy clinical trial results collectively provide robust evidence across diverse patient populations and treatment durations.

Wegovy Clinical Trial Results: Key Efficacy Endpoints and Outcomes

The primary efficacy measure across wegovy clinical trial results was percentage change in body weight from baseline to week 68. In STEP 1, 86.4% of participants on semaglutide achieved ≥5% weight loss (versus 31.5% on placebo), whilst 69.1% achieved ≥10% weight loss (versus 12.0% on placebo)[1]. Notably, 50.5% of Wegovy-treated participants reached ≥15% weight reduction, a threshold associated with significant metabolic health improvements. These proportions far exceeded those observed with earlier weight management medications licensed in the UK.

Secondary endpoints in the wegovy clinical trial results included changes in waist circumference, systolic blood pressure, and lipid profiles. Participants treated with semaglutide 2.4mg experienced mean waist circumference reductions of 13.5 cm compared to 4.1 cm with placebo[1]. Systolic blood pressure decreased by an average of 6.2 mmHg in the Wegovy group. HbA1c levels in participants with prediabetes at baseline showed greater reductions with active treatment, and 84.1% of these individuals reverted to normoglycaemia compared to 47.8% on placebo[2]. These cardiometabolic benefits complement the weight loss outcomes observed across trials.

Patient-Reported Outcomes in Wegovy Trials

Beyond objective measures, wegovy clinical trial results incorporated patient-reported outcome tools to assess quality of life and physical functioning. The STEP 1 trial utilised the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) questionnaire, demonstrating significantly greater improvements in physical function, public distress, and total score domains for semaglutide-treated participants versus placebo[1]. These findings suggest that the weight loss achieved with Wegovy translates into meaningful improvements in daily functioning and wellbeing as experienced by patients themselves.

Safety Profile: Adverse Events in Wegovy Clinical Trial Results

The wegovy clinical trial results provide comprehensive safety data from long-term exposure to semaglutide 2.4mg. Gastrointestinal adverse events were the most frequently reported, occurring in 74% of Wegovy participants versus 47% of placebo recipients in STEP 1[1]. The most common specific events included nausea (44%), diarrhoea (32%), vomiting (25%), and constipation (24%), typically mild to moderate in severity and transient, peaking during dose escalation phases. Serious adverse events occurred in 9.8% of semaglutide participants versus 6.4% of placebo, though most were not treatment-related[1].

Discontinuation rates due to adverse events in wegovy clinical trial results ranged from 4.5% to 7.0% across STEP trials for semaglutide arms, compared to 2.4% to 3.2% for placebo[1][2]. Gallbladder-related events (cholelithiasis, cholecystitis) occurred in approximately 2.6% of Wegovy-treated participants versus 1.2% on placebo, consistent with rapid weight loss effects seen with other treatments[3]. No increased risk of pancreatitis, major adverse cardiovascular events, or medullary thyroid carcinoma was observed during the trials, though semaglutide carries a boxed warning regarding thyroid C-cell tumours based on rodent studies. All prescription of Wegovy at Cured Pharmacy follows clinical assessment by UK-registered prescribers who evaluate individual risk factors and contraindications.

Treatment Type Average Weight Loss Starting Price
Wegovy GLP-1 injection (weekly) 12-15% (68 weeks) from £89.00
Mounjaro GIP/GLP-1 injection (weekly) 15-22% (72 weeks) from £145.00
Saxenda GLP-1 injection (daily) 5-8% (56 weeks) from £68.00
Orlistat Lipase inhibitor (oral) 3-5% (12 months) from £32.00
Mysimba Naltrexone/bupropion (oral) 4-6% (56 weeks) from £125.95

Long-Term Wegovy Clinical Trial Results: STEP 5 Extended Duration Study

The STEP 5 trial extended the observation period to 104 weeks, providing crucial long-term wegovy clinical trial results for sustained weight management[4]. This randomised trial enrolled 304 adults with obesity who received once-weekly semaglutide 2.4mg or placebo for two years. At week 104, participants on Wegovy achieved a mean weight loss of 15.2% from baseline, compared to 2.6% with placebo—demonstrating that weight reduction not only persists but continues to accrue beyond the first year of treatment[4].

These extended wegovy clinical trial results address a critical question in obesity medicine: whether pharmacotherapy can deliver durable weight loss. The STEP 5 findings showed that 77.1% of semaglutide participants achieved ≥10% weight loss at two years, and 40.0% reached ≥20% reduction[4]. Importantly, the safety profile remained consistent with shorter-duration trials, with no new adverse signals emerging during prolonged exposure. For UK patients seeking evidence-based weight management through Cured Pharmacy, these long-term data provide reassurance that Wegovy's benefits can be maintained with continued treatment under appropriate medical supervision.

Weight Regain After Wegovy Discontinuation

The STEP 4 trial specifically examined what happens when Wegovy is stopped after initial weight loss. Participants who discontinued semaglutide and switched to placebo regained approximately two-thirds of their lost weight over the subsequent 48 weeks[3]. These wegovy clinical trial results underscore that obesity is a chronic condition requiring ongoing management, and that semaglutide works through active pharmacological mechanisms rather than simply initiating behavioural changes that persist independently. UK prescribers at Cured Pharmacy discuss long-term treatment strategies during clinical assessments to set realistic expectations for sustained weight management.

Wegovy Clinical Trial Results in Specific UK-Relevant Populations

Several STEP trials generated wegovy clinical trial results particularly relevant to UK patient demographics. STEP 2 enrolled adults with type 2 diabetes and BMI ≥27 kg/m², a population representing approximately 90% of UK adults with diabetes who are overweight or obese according to NHS data[2]. In this trial, semaglutide 2.4mg produced 9.6% mean weight loss and greater HbA1c reductions (-1.6%) compared to placebo (-0.4%), addressing both weight and glycaemic control simultaneously[2].

The STEP 8 trial compared semaglutide 2.4mg directly against liraglutide 3.0mg (Saxenda), another GLP-1 receptor agonist licensed for weight management in the UK[5]. This head-to-head wegovy clinical trial results showed semaglutide delivered superior weight loss: 15.8% versus 6.4% at 68 weeks. Twice as many participants on Wegovy achieved ≥15% weight reduction (70% versus 25%)[5]. For UK patients comparing treatment options at Cured Pharmacy, these comparative data inform evidence-based decision-making alongside cost considerations—Wegovy is available from £69.00 with once-weekly dosing versus daily injections required for liraglutide.

Accessing Wegovy Based on Clinical Trial Results: UK Availability at Cured Pharmacy

The compelling wegovy clinical trial results led to MHRA licensing in 2021 and subsequent NICE approval for NHS prescription under specific criteria (BMI ≥35 kg/m² or ≥32.5 kg/m² for certain ethnic groups, plus weight-related comorbidity)[6]. However, NHS supply constraints mean many eligible UK patients face extended waiting times. Cured Pharmacy offers private access to genuine UK-licensed Wegovy from £69.00, with transparent upfront pricing and free online consultation completed in under three minutes by UK-registered prescribers.

Every prescription at Cured Pharmacy follows the same clinical assessment protocols that guided participant selection in the wegovy clinical trial results. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team evaluate medical history, contraindications, and suitability based on MHRA-approved criteria. Treatment includes the same dose-escalation schedule used in STEP trials to minimise gastrointestinal side effects, starting at 0.25mg weekly and increasing to the maintenance dose of 2.4mg over 16-20 weeks. Patients receive ongoing support and can access prescriber advice throughout their treatment journey, mirroring the structured protocols that produced the robust efficacy outcomes seen in clinical trials.

Combining Wegovy with Lifestyle Interventions

All wegovy clinical trial results included lifestyle intervention components—participants received counselling on reduced-calorie diets (500 kcal/day deficit) and increased physical activity (150 minutes/week)[1][2]. STEP 3 intensified this behavioural support and achieved 16.0% mean weight loss, the highest in the programme[2]. These findings emphasise that Wegovy works synergistically with diet and exercise rather than replacing them. UK patients starting treatment through Cured Pharmacy receive guidance on evidence-based lifestyle modifications to optimise outcomes, reflecting the multimodal approach that underpinned the clinical trial successes.

Scientific References

  1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
  2. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
  3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
  4. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
  5. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., et al. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. [accessed 15 August 2026]
  6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
  7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
  8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
  9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

What were the main wegovy clinical trial results for weight loss?
The STEP trials showed Wegovy (semaglutide 2.4mg) produced 12-15% average weight loss over 68 weeks, with 86% of participants achieving ≥5% weight reduction and 69% achieving ≥10% weight loss.
How long did participants stay on Wegovy in clinical trials?
Most STEP trials ran for 68 weeks, whilst STEP 5 extended to 104 weeks (two years), demonstrating sustained weight loss of 15.2% with continued treatment.
Did wegovy clinical trial results show benefits beyond weight loss?
Yes—trials demonstrated reductions in waist circumference (average 13.5cm), blood pressure (6.2mmHg systolic), and improvements in prediabetes markers, with 84% of participants reverting to normal glucose levels.
What side effects appeared in wegovy clinical trial results?
Gastrointestinal events (nausea, diarrhoea, vomiting) were most common, typically mild-moderate and transient during dose escalation. Discontinuation rates due to side effects were 4.5-7.0% across trials.
How do wegovy clinical trial results compare to other weight loss medications?
Head-to-head STEP 8 trial showed Wegovy delivered 15.8% weight loss versus 6.4% with Saxenda at 68 weeks, with twice as many participants achieving ≥15% reduction.
Were UK patients included in the wegovy clinical trial results?
Yes—the STEP programme included trial sites across multiple countries including the UK, with results leading to MHRA licensing in 2021 and NICE approval for NHS prescription.
Can I access Wegovy in the UK based on these trial results?
Wegovy is available through Cured Pharmacy from £69.00 following free online assessment by UK-registered prescribers who evaluate eligibility using the same clinical criteria applied in trials.
What happens if I stop Wegovy after losing weight?
STEP 4 trial showed participants who discontinued Wegovy regained approximately two-thirds of lost weight over 48 weeks, indicating obesity requires ongoing treatment for sustained management.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 15 August 2026

Last updated on 15 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 15 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (15 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.